Skip to main content
Market Outlook Snapshot Market Dynamics Regional Forecast Country Insights Segment Analysis Competitive Landscape Industry News FAQ
On This Report

Hemostasis and Tissue Sealing Agents Market Size & Growth Forecast 2027–2036, By Segments (Product, End-use, Material, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Report ID: FBI 11241| Published Date: Jul-2026| Format: PDF, Excel
Market Outlook

Market Size and Growth Outlook

Hemostasis and Tissue Sealing Agents Market size was more than USD 10.2 billion in 2026 and is set to grow at a 8.55% CAGR between 2027 and 2036, surpassing USD 23.17 billion by 2036. The industry revenue for 2027 is assessed at USD 10.93 billion.

Base Year Value (2026)
USD 10.2 billion
CAGR (2027-2036)
8.55%
Forecast Year Value (2036)
USD 23.17 billion
Historical Data Period
2022-2026
Largest Region
North America
Forecast Period
2027-2036

Get more details on this report

Request Free Sample Report
Snapshot

Hemostasis and Tissue Sealing Agents Market Intelligence Snapshot

Regional Market Dynamics

  • North America leads due to high surgical volumes, mature healthcare infrastructure, and established clinical adoption of advanced bleeding control and tissue management solutions.
  • Asia Pacific is projected to grow at a 10.28% CAGR, supported by rising surgical activity, improving hospital capacity, and wider adoption of modern operative techniques.

Segment Momentum

  • Topical Hemostats held a 64.02% share in 2026 due to their broad surgical applicability, ease of use, and consistent role in controlling bleeding across both routine and complex procedures.
  • Ambulatory Surgical Centers are the fastest-growing end-use segment as more procedures shift to outpatient settings that prioritize efficient workflows, shorter patient stays, and dependable surgical outcomes.

Market Expansion Drivers

  • Rising chronic disease surgeries increasing demand for advanced hemostatic and tissue sealing solutions.
  • Expanding minimally invasive cardiovascular and urological procedures accelerating topical hemostat utilization.
  • Hospital focus on faster recovery outcomes strengthening adoption of bioactive surgical sealants.

Leading Market Participants

  • Leading companies in the hemostasis and tissue sealing agents market include Johnson & Johnson (United States), Medtronic plc (Ireland), Baxter International Inc. (United States), B. Braun Melsungen AG (Germany), Ethicon, Inc. (United States), Integra LifeSciences Holdings Corporation (United States), Smith & Nephew plc (United Kingdom), BD (Becton, Dickinson and Company) (United States), CryoLife, Inc. (United States), Teleflex Incorporated (United States).

Forecast Snapshot

Global Market Forecast Snapshot

Market Outlook

  • 2026 Market Size: USD 10.2 billion
  • 2027 Estimated Market Size: USD 10.93 billion.
  • Projected Market Size: USD 23.17 billion by 2036
  • Growth Forecast: 8.55% CAGR (2027-2036)

Regional and Segment Outlook

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Topical Hemostat (Product) | Hospitals (End-use) | Gelatin-based Topical Hemostats (Material) | General Surgery (Application)
  • Emerging Opportunity Segment: Adhesive & Tissue Sealant (Product) | Ambulatory Surgical Centers (End-use) | Polysaccharide-based Topical Hemostats (Material) | Cardiovascular Surgery (Application)
Market Dynamics

Market Growth Drivers and Industry Trends

Rising chronic disease surgeries increasing demand for advanced hemostatic and tissue sealing solutions

The growing volume of surgical procedures associated with chronic diseases will drive the hemostasis and tissue sealing agents market growth as healthcare providers require effective methods for controlling bleeding and supporting wound closure during complex interventions. Conditions requiring cardiovascular, gastrointestinal, orthopedic, and other surgical treatments can create situations in which conventional methods of bleeding control are insufficient or difficult to apply. Advanced hemostatic agents can provide localized bleeding management, while tissue sealants can assist in closing surgical sites and supporting tissue approximation. Their use can be particularly relevant when surgeons encounter diffuse bleeding, difficult anatomical locations, or tissues where conventional suturing and cauterization may have limitations.

Expanding minimally invasive cardiovascular and urological procedures accelerating topical hemostat utilization

Growing adoption of minimally invasive techniques will propel the hemostasis and tissue sealing agents market growth as surgeons increasingly require localized bleeding-control solutions that can be applied effectively within constrained procedural fields. Cardiovascular and urological interventions often involve delicate tissues and access routes where achieving precise hemostasis can be challenging. Topical hemostats can supplement conventional techniques by providing localized control of bleeding without requiring extensive manipulation of surrounding tissue. As procedural approaches increasingly emphasize smaller access points, reduced tissue disruption, and efficient operative management, the role of topical products in addressing bleeding at difficult-to-reach sites is becoming more relevant across specialized surgical settings.

Hospital focus on faster recovery outcomes strengthening adoption of bioactive surgical sealants

Hospitals are placing greater emphasis on efficient postoperative recovery and improved surgical outcomes, supporting growth in the hemostasis and tissue sealing agents market as bioactive sealants offer additional tools for managing surgical sites. These products can assist with tissue sealing and bleeding control while supporting surgical techniques designed to minimize tissue trauma and postoperative complications. Their application can be useful in procedures where secure closure and controlled hemostasis are important to the recovery process, particularly when conventional closure methods alone may not provide the desired result. Increasing attention to operating-room efficiency, patient recovery pathways, and the broader management of postoperative care is encouraging clinicians to consider advanced sealing technologies alongside established surgical methods.

Growth Driver Impact on CAGR Regulatory Influence Geographic Relevance Adoption Rate Impact Timeline
Rising chronic disease surgeries increasing demand for advanced hemostatic and tissue sealing solutions 2.00% Moderate North America, Asia Pacific High Near Term
Expanding minimally invasive cardiovascular and urological procedures accelerating topical hemostat utilization 1.80% High North America, Europe High Mid Term
Hospital focus on faster recovery outcomes strengthening adoption of bioactive surgical sealants 1.30% Moderate Asia Pacific, Middle East & Africa Emerging Mid Term
Custom Research

Unlock insights tailored to your business with our bespoke market research solutions.

Click to get your customized report now.

Request Customization →
Regional Forecast

Regional Demand Dynamics

Hemostasis and Tissue Sealing Agents Market
Largest Region
North America
XX% Market Share in 2026

North America (Largest Region)

The hemostasis and tissue sealing agents market was led by North America in 2026, supported by sophisticated surgical infrastructure, high procedural volumes, and strong adoption of advanced technologies for controlling bleeding during complex interventions. Hospitals and surgical centers are increasingly using topical hemostatic products and tissue sealants to improve procedural efficiency and support effective wound management across a broad range of surgical specialties. The region’s established healthcare systems, emphasis on patient safety, and ongoing adoption of minimally invasive procedures are also contributing to demand for products that can provide reliable bleeding control and tissue closure. Continued clinical innovation and investment in surgical care infrastructure are strengthening the region’s established market position.

Asia Pacific (Fastest-Growing Region)

Asia Pacific is poised for the fastest growth as healthcare infrastructure expands, surgical access improves, and demand for advanced operative care increases across the region. Rising healthcare expenditure and modernization of hospitals are enabling greater adoption of specialized surgical products, while the expansion of minimally invasive and complex procedures is creating additional demand for effective hemostatic solutions. Increasing awareness of improved surgical outcomes and the need to reduce procedure-related complications are also encouraging healthcare providers to incorporate advanced tissue sealing technologies into clinical practice. As medical infrastructure continues to develop across emerging economies, adoption is expected to broaden beyond major metropolitan healthcare centers.

Parameter North America Asia Pacific Europe Latin America MEA
Innovation Hub i Scale Nascent Developing Advanced
Cost-Sensitive Region i Scale Low Medium High
Regulatory Environment i Scale Restrictive Neutral Supportive
Demand Drivers i Scale Weak Moderate Strong
Development Stage i Scale Emerging Developing Developed
Adoption Rate i Scale Low Medium High
New Entrants / Startups i Scale Sparse Moderate Dense
Macro Indicators i Scale Weak Stable Strong
Country Insights

Key Country Insights

Germany 🇩🇪

Precision Surgical Materials

Germany emphasizes the use of high-precision hemostatic and sealing products in technologically advanced surgical environments. Clinical adoption is driven by demand for consistent performance in complex procedures across well-equipped hospital systems.

France 🇫🇷

Clinical Standardization Drive

France prioritizes standardized use of hemostasis and tissue sealing agents within hospital networks focused on consistent surgical outcomes. Procurement decisions are guided by clinical efficacy and integration into established surgical protocols.

Italy 🇮🇹

Surgical Efficiency Focus

Italy emphasizes hemostasis and tissue sealing agents that enhance efficiency in surgical workflows across public and private hospitals. Adoption is supported by demand for reliable products that reduce operative time and improve post-surgical outcomes.

Japan 🇯🇵

Minimally Invasive Preference

Japan focuses on hemostasis and tissue sealing agents aligned with its strong preference for minimally invasive surgical techniques. Healthcare providers prioritize products that support reduced recovery times and high procedural safety standards.

South Korea 🇰🇷

Surgical Innovation Uptake

South Korea is increasing adoption of modern sealing agents alongside expanding advanced surgical capabilities in tertiary hospitals. Clinicians emphasize product reliability in laparoscopic and endoscopic procedures across the country’s evolving healthcare infrastructure.

United States 🇺🇸

Advanced Surgical Adoption

The U.S. is prioritizing advanced hemostasis and tissue sealing agents across high-volume surgical procedures, particularly in cardiovascular and minimally invasive surgeries. Hospitals and surgical centers increasingly adopt bioactive sealants to reduce operative complications and improve procedural efficiency.

Segment Analysis

Segment Leadership and Growth Trends

Hemostasis and Tissue Sealing Agents Market Share (%), by Product, 2026

Topical Hemostat
Adhesive & Tissue Sealant
Adhesion Barrier Products

Go beyond the chart, access full insights & data tables

Request Free Sample Report

Product Segment Analysis: Topical Hemostat (Largest Segment) vs Adhesive & Tissue Sealant (Fastest-Growing Segment)

The topical hemostat segment led the hemostasis and tissue sealing agents market with a 64.02% share in 2026, supported by its broad use in surgical procedures to control bleeding and improve procedural efficiency. These agents are particularly valuable where conventional hemostatic techniques may be insufficient, providing localized bleeding control across a range of surgical settings. Their established clinical use, ease of application, and suitability for managing diffuse bleeding continue to reinforce demand. Increasing surgical volumes and the emphasis on reducing intraoperative blood loss are further supporting the segment's strong market position.

Adhesive & tissue sealants are gaining momentum as surgical practice increasingly emphasizes rapid wound closure, tissue approximation, and effective control of bleeding at challenging anatomical sites. Their ability to create a protective barrier and support tissue repair makes them attractive across procedures where conventional closure methods can be difficult or time-consuming. Growing interest in minimally invasive techniques and products that can simplify surgical workflows is strengthening adoption, while continued innovation in biocompatible formulations is supporting broader clinical use.

End-use Segment Analysis: Hospitals (Largest Segment) vs Ambulatory Surgical Centers (Fastest-Growing Segment)

Hospitals represented the largest share of the hemostasis and tissue sealing agents market in 2026, reflecting their role as major centers for complex surgeries, trauma care, and procedures requiring advanced bleeding-control solutions. Their extensive surgical infrastructure and access to specialized clinical teams support consistent utilization of topical hemostats and tissue-sealing products. The increasing focus on surgical safety, efficient operating-room workflows, and improved patient outcomes continues to sustain demand across hospital-based procedures.

Ambulatory surgical centers are expanding their use of hemostasis and tissue sealing agents as more procedures transition toward outpatient settings. These facilities prioritize efficient procedures, shorter recovery periods, and streamlined postoperative management, increasing the value of products that can support rapid bleeding control and tissue closure. Growing adoption of minimally invasive surgery and the broader shift toward cost-efficient, same-day care are creating favorable conditions for wider utilization of these agents in ambulatory environments.

Segment Sub-Segment Largest Segment Fastest Growing
Product Topical Hemostat, Adhesive & Tissue Sealant, Adhesion Barrier Products Topical Hemostat Adhesive & Tissue Sealant
End-use Hospitals, Ambulatory Surgical Centers, Others Hospitals Ambulatory Surgical Centers
Material Gelatin-based Topical Hemostats, Collagen-based Topical Hemostats, ORC-based Topical Hemostats, Polysaccharide-based Topical Hemostats Gelatin-based Topical Hemostats Polysaccharide-based Topical Hemostats
Application General Surgery, Neurosurgery, Vascular Surgery, Cardiovascular Surgery, Others General Surgery Cardiovascular Surgery
Read our Research Approach →
Competitive Landscape

Competitive Landscape and Market Positioning

Major players in the hemostasis and tissue sealing agents market:

1. Johnson & Johnson (United States)

2. Medtronic plc (Ireland)

3. Baxter International Inc. (United States)

4. B. Braun Melsungen AG (Germany)

5. Ethicon Inc. (United States)

6. Integra LifeSciences Holdings Corporation (United States)

7. Smith & Nephew plc (United Kingdom)

8. BD (Becton Dickinson and Company) (United States)

9. CryoLife Inc. (United States)

10. Teleflex Incorporated (United States)

The hemostasis and tissue sealing agents market is witnessing sustained innovation aimed at improving surgical efficiency and patient recovery outcomes. Manufacturers are developing advanced sealing formulations designed for faster clotting performance, reduced blood loss, and enhanced compatibility across minimally invasive procedures. Growing emphasis on surgeon feedback and procedure-specific solutions is also influencing product refinement strategies and driving competitive differentiation within the market.

Company Market Share Company Revenue Revenue CAGR (%) Product Portfolio Geographic Presence Innovation / R&D Focus Strategic Developments
Johnson & Johnson (United States)
Medtronic plc (Ireland)
Baxter International Inc. (United States)
B. Braun Melsungen AG (Germany)
Ethicon Inc. (United States)
Integra LifeSciences Holdings Corporation (United States)
Smith & Nephew plc (United Kingdom)
BD (Becton Dickinson and Company) (United States)
CryoLife Inc. (United States)
Teleflex Incorporated (United States).
🔒 This section is available as a standalone purchase. Buy only the data you need. Inquire Before Buying
Industry News

Industry Development/News

Company Name Date Key Development
Merit Medical Systems May-25 Merit Medical Systems acquired Biolife for USD 120 million, integrating a specialized hemostatic device manufacturer into its operations. This acquisition strategically expands Merit’s acute bleeding control portfolio, reinforcing its competitive capabilities in surgical trauma management and providing a broader suite of specialized hemostasis solutions for healthcare providers.
Baxter International Apr-25 Baxter International launched a room-temperature stable version of its Hemopatch Sealing Hemostat. By eliminating the requirement for specialized refrigerated storage, this innovation significantly simplifies operating-room logistics and inventory management, allowing for increased availability and faster clinical access during time-critical surgical procedures.
Ethicon Nov-23 Ethicon (Johnson & Johnson MedTech) received European approval for Ethizia, a hemostatic sealing patch utilizing synthetic polymer technology. The patch features a dual-sided active matrix adaptable for both open and minimally invasive surgery; clinical trials demonstrated rapid efficacy, achieving hemostasis in 30 seconds for 80% of patients, outperforming traditional fibrin sealant alternatives.
Integra LifeSciences Dec-22 Integra LifeSciences acquired Surgical Innovation Associates, a strategic move to broaden its surgical solutions portfolio. The acquisition provides Integra with new assets and technology to strengthen its market position in advanced surgical wound management and tissue sealing, reflecting a continued commitment to integrating innovative medical devices into its comprehensive surgical care ecosystem.
Report Customization

Customize Your Report

Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.

1 Custom Segments 2 Custom TOC 3 Related Reports

Hemostasis and Tissue Sealing Agents Market — Custom Segments

Segment Sub-Segment
Bleeding Severity Minor & Capillary Bleeding, Moderate Bleeding, Severe & Uncontrolled Bleeding
Surgical Approach Open Surgery, Minimally Invasive Surgery, Endoscopic Surgery, Robotic-Assisted Surgery
Purchase Mode Direct Institutional Procurement, Group Purchasing Organization Procurement, Distributor-Mediated Procurement

Hemostasis and Tissue Sealing Agents Market — Custom TOC

Custom Chapter Custom Details
Hospital Procurement and Tender Intelligence
  • Hospital Purchasing Priorities and Procurement Criteria
  • Tender Structures and Supplier Evaluation Dynamics
  • Clinical, Economic, and Operational Selection Factors
  • Contracting Models and Purchasing Influencers
  • Procurement Implications for Product Positioning
Surgical Procedure Opportunity Assessment
  • Procedure-Level Demand Drivers and Clinical Applications
  • Opportunity Across Surgical Specialties and Procedure Settings
  • Procedure Complexity and Hemostasis Requirements
  • Adoption Opportunities Across Open, Minimally Invasive, and Advanced Procedures
  • Emerging Procedure Applications and Commercial Priorities
Reimbursement and Market Access Landscape
  • Reimbursement Structures and Coverage Considerations
  • Health Economic Evidence and Value Demonstration Requirements
  • Market Access Barriers Across Healthcare Systems
  • Payer and Provider Value Expectations
  • Access Strategies and Commercialization Priorities

Need a different cut of the data?

Request Custom Research
Frequently Asked Questions

What is the market valuation of hemostasis and tissue sealing agents?

The market valuation of the hemostasis and tissue sealing agents is USD 10.93 billion in 2027.

What are the growth projections for the hemostasis and tissue sealing agents industry?

Hemostasis and Tissue Sealing Agents Market size was more than USD 10.2 billion in 2026 and is set to grow at a 8.55% CAGR between 2027 and 2036, surpassing USD 23.17 billion by 2036.

How are complex surgical procedures influencing demand for advanced hemostasis and tissue sealing solutions?

Increasing procedural complexity is driving hospitals toward products that improve bleeding control and surgical efficiency. Advanced hemostats and sealants are becoming important tools for managing challenging cases and supporting reliable intraoperative outcomes.

Why are minimally invasive procedures accelerating adoption of topical hemostatic agents?

Growth in minimally invasive workflows is increasing demand for precise, easy-to-apply products that fit confined surgical environments. Flowable, sprayable, and patch-based agents align with efforts to reduce procedural trauma and improve efficiency.

Why do Topical Hemostats dominate the hemostasis and tissue sealing agents market?

Topical Hemostats held a 64.02% share in 2026 due to their broad surgical applicability, ease of use, and consistent role in controlling bleeding across both routine and complex procedures.

Which end-use segment is expanding fastest in the hemostasis and tissue sealing agents market?

Ambulatory Surgical Centers are the fastest-growing end-use segment as more procedures shift to outpatient settings that prioritize efficient workflows, shorter patient stays, and dependable surgical outcomes.

What makes North America the largest market for hemostasis and tissue sealing agents?

North America leads due to high surgical volumes, mature healthcare infrastructure, and established clinical adoption of advanced bleeding control and tissue management solutions.

How is Asia Pacific expanding in the hemostasis and tissue sealing agents market?

Asia Pacific is projected to grow at a 10.28% CAGR, supported by rising surgical activity, improving hospital capacity, and wider adoption of modern operative techniques.

Which companies dominate the hemostasis and tissue sealing agents landscape?

Leading companies in the hemostasis and tissue sealing agents market include Johnson & Johnson (United States), Medtronic plc (Ireland), Baxter International Inc. (United States), B. Braun Melsungen AG (Germany), Ethicon, Inc. (United States), Integra LifeSciences Holdings Corporation (United States), Smith & Nephew plc (United Kingdom), BD (Becton, Dickinson and Company) (United States), CryoLife, Inc. (United States), Teleflex Incorporated (United States).
Testimonials

Our Clients

"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."

Project Manager
Siemens Healthcare

"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."

Research and Development (R&D) Manager
GC Biopharma

"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."

Quality Assurance Manager
Medtronic
THE RESEARCH BEHIND THIS REPORT

Our Research Team & Methodology

Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.

THIS REPORT'S RESEARCH VERTICAL

Research Team Overview

♢
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.

Prepared by the Healthcare & Medical Devices Research Team

10+
Industry Verticals
100+
Countries Analyzed
5–7
Days Standard
Delivery
12k+
Research Reports
Published
On-
Demand
Customized Research
Available
6
Months Analyst
Support
PDF + XLS
Report Deliverables

Trust & Compliance

☷D&B D-U-N-S
♢GDPR & CCPA Compliant
♙ISO 9001 Certified (ISO 9001:2015)
♙SSL Encryption
▭Secure Payments
✓Confidential Handling

Research Domains

10 coverage areas
Medical Devices & Equipment Diagnostic Imaging Clinical Diagnostics Digital Health & Telemedicine Patient Monitoring Systems Surgical & Minimally Invasive Technologies Healthcare IT & Data Systems Biotechnology & Life Sciences Pharmaceutical Technologies Healthcare Delivery & Services

Research Intelligence

Executive Leadership
Product & Technology Experts
Manufacturing & Operations Leaders
Procurement & Supply Chain Professionals
Sales & Commercial Executives
Channel Partners & Distribution Networks
Enterprise Buyers & End Users
Industry Consultants & Regulatory Experts

Research Workflow & Quality Assurance

📥
01

Data Collection

Verified information gathered through primary and secondary research.

🔍
02

Data Triangulation

Cross-validation using multiple independent data sources.

📈
03

Forecast Modelling

Market estimates developed using historical trends and analytical models.

👨‍💼
04

Analyst Validation

Findings reviewed by domain experts for accuracy and consistency.

📝
05

Editorial & Quality Review

Final editorial, quality, and compliance checks before publication.

✅
06

Final Publication

Released after successful completion of the internal review process.

Report Coverage

📊 Market Assessment

  • Market Size & Forecast
  • Market Segmentation
  • Regional Analysis
  • Growth Drivers & Challenges
  • Market Dynamics

🏢 Competitive Intelligence

  • Competitive Landscape
  • Company Profiles
  • Competitive Benchmarking
  • Mergers & Acquisitions
  • Market Share Analysis or Key Company Strategies

🔍 Strategic Analysis

  • Value Chain Analysis
  • Porter's Five Forces
  • PESTLE Analysis
  • Pricing Trends
  • Supply-Demand Analysis

🚀 Future Outlook

  • Technology Landscape
  • Regulatory Landscape
  • Investment & Funding Landscape
  • Emerging Opportunities
  • Future Market Outlook

Have a question about this report or need a custom scope?

Request Customization
License

Select License Type

Single User
US$ 4,250
Buy Now
Corporate User
US$ 6,150
Buy Now

Want this data scoped to your exact question?

Tell us the segments, regions, or competitors you need answered — an analyst will confirm scope before any custom work starts.

Talk to an Analyst →